Analysis of analgesic effect of patient-controlled subcutaneous infusion of sufentanil in patients with advanced cancer pain

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011280

Enrollment

Unknown

Registered

2017-05-02

Start date

2017-05-03

Completion date

Unknown

Last updated

2017-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancerous pain

Interventions

one:Subcutaneous infusion of morphine

two:Subcutaneous infusion of sufentanil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18-year-old and elder cancer patients; 2. VAS> 5 points or more; KPS=40 points; 3. Patients with advanced cancer pain can not be given orally; or oral morphine dose of more than 100mg / d; or pain control is not satisfied; or can not tolerate opioid side effects; 4. Voluntarily participate in this study, signed informed consent.

Exclusion criteria

Exclusion criteria: 1. There are objections to the treatment of this trial; 2. The general situation is very poor, can not describe the symptoms can not be active with the initiative; 3. Allergy to its related drugs and accessories; 4. can not tolerate treatment; 5. Consciousness disorder; 6. have severe infection, respiratory insufficiency; 7. Contraindications to test drugs; 8. Suspect or indeed a patient with a history of drug abuse; 9. Pregnant, lactating women; or subjects who have a pregnancy plan within one month of the trial (also including male subjects).

Design outcomes

Primary

Measure	Time frame
VAS scores;	—

Secondary

Measure	Time frame
SF-36 scores;PSQI scores;	—

Countries

China

Contacts

Public ContactSong Tao

The First Affiliated Hospital of China Medical University

songtaocmu@163.com+86 15840599900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026